Related Experiment Video
Updated: Dec 24, 2025
Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
Published on: September 8, 2017
69-Year-Old Man With Castration-Resistant Prostate Cancer Progressing After Docetaxel and Androgen Receptor-Targeting
Abstract:
KEY POINTS • The prognosis for patients with mCRPC has improved over the last few years due to the introduction of novel agents. • The optimal sequence of administering these therapeutic agents remains as a moving target and is not well established. Decisions are usually made according to patients' clinical conditions and disease characteristics, and the safety profile and availability of new drugs. • Recently, cabazitaxel improved outcomes in the third-line setting after docetaxel and an ARTA. Olaparib is an additional option for second- and third-line treatment in those with alterations in BRCA1, BRCA2, and ATM. • Understanding the mechanisms of resistance may provide a rationale for suggesting specific strategies. • A subset of patients may benefit from molecularly targeted therapies, which highlights the importance of genomic testing in the castration-resistant setting. • Immunotherapy may provide benefit to some subsets of patients, such as those with MSI-high tumors. Studies regarding combination therapy with immune checkpoint inhibitors are ongoing.
Insights
Novel agents have improved outcomes for metastatic castration-resistant prostate cancer (mCRPC). Treatment sequencing is evolving, with cabazitaxel and olaparib offering new options, and genomic testing guiding personalized strategies.
Area of Science:
- Oncology
- Medical Therapeutics
Background:
- The prognosis for metastatic castration-resistant prostate cancer (mCRPC) has significantly improved with the advent of novel therapeutic agents.
- However, the optimal sequencing of these treatments remains a complex and evolving challenge.
Observation:
- Recent advancements include cabazitaxel demonstrating efficacy in the third-line setting post-docetaxel and androgen receptor targeted agents (ARTA).
- Olaparib presents a new option for second- and third-line treatment in patients with specific BRCA1, BRCA2, and ATM alterations.
Findings:
- Understanding resistance mechanisms is crucial for developing effective treatment strategies.
- Genomic testing is increasingly important in the castration-resistant setting to identify patients who may benefit from molecularly targeted therapies.
- Immunotherapy, particularly for patients with MSI-high tumors, shows promise, with ongoing research into combination therapies.
Implications:
- Personalized treatment approaches, guided by genomic profiling, are becoming essential for managing mCRPC.
- The evolving landscape of mCRPC treatment necessitates continuous evaluation of drug sequencing and emerging therapeutic modalities like immunotherapy.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:56Treatment Resistant Cancers